SCHEMBL3748862

SCHEMBL3748862

CC[C@]1(C#N)[C@H]2C[C@H]2[C@H]2[C@@H]3[C@@H](C)CC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 4/20 0.54
CYP19A1 P11511 4/20 0.53
ALDH1A1 P00352 2/20 0.45
PGR P06401 3/20 0.42
AR P10275 3/20 0.42
LMNA P02545 2/20 0.41
NR3C1 P04150 2/20 0.41
HTR2B P41595 2/20 0.41
ABCC4 O15439 1/20 0.41
ABCB11 O95342 1/20 0.41
CHRM2 P08172 1/20 0.41
HTR2A P28223 1/20 0.41
SRD5A1 P18405 1/20 0.41
SRD5A2 P31213 1/20 0.41
HSD17B10 Q99714 2/20 0.40
CYP3A4 P08684 2/20 0.40
SERPINA6 P08185 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3751402 1.00 SHBG (0.54) SHBGCYP19A1ALDH1A1PGRAR
SCHEMBL3758865 0.84 SHBG (0.53) SHBGCYP19A1ALDH1A1PGRAR
SCHEMBL10089126 0.80 AR (0.62) SHBGALDH1A1PGRARLMNA
SCHEMBL4217361 0.80 AR (0.62) SHBGALDH1A1PGRARLMNA
SCHEMBL4215376 0.80 AR (0.62) SHBGALDH1A1PGRARLMNA
SCHEMBL3746809 0.77 SHBG (0.54) SHBGCYP19A1ALDH1A1PGRAR
SCHEMBL3756586 0.76 CYP19A1 (0.52) CYP19A1ALDH1A1PGRARLMNA
SCHEMBL3748864 0.75 SHBG (0.53) SHBGCYP19A1ALDH1A1ARCYP3A4
SCHEMBL3749070 0.75 SHBG (0.57) SHBGCYP19A1ALDH1A1PGRAR
SCHEMBL3748477 0.75 SHBG (0.57) SHBGCYP19A1ALDH1A1PGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE BAYER SCHERING PHARMA AG (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE HSD17B11, HSD17B7, NR5A1 SHBG 24/4885CYP19A1 14/4885ALDH1A1 1039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.